Victor A. Kostyuchenko

Victor A. Kostyuchenko

Auto-generated profile, based on publicly available information

Victor A. Kostyuchenko

Program in Emerging Infectious Diseases, Duke-NUS Graduate Medical School, Singapore

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2002 in Nature
Verified
Journal Article
Closed access
PDF file
SKShuji Kanamaru
Shuji Kanamaru
PLPetr Leiman
Petr Leiman
VKVictor A. Kostyuchenko
Victor A. Kostyuchenko
PCPaul R. Chipman
Paul R. Chipman
VMVadim V. Mesyanzhinov
Vadim V. Mesyanzhinov
MRMichael G. Rossmann
Michael G. Rossmann

10 February 2008 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
SLShee-Mei Lok
Shee-Mei Lok
VKVictor Kostyuchenko
Victor Kostyuchenko
GNGrant E Nybakken
Grant E Nybakken
HHHeather A Holdaway
Heather A Holdaway
ABAnthony J Battisti
Anthony J Battisti
MRMichael G Rossmann
Michael G Rossmann

3 July 2015 in Science
Verified
Journal Article
Closed access
PDF file
GFGuntur Fibriansah
Guntur Fibriansah
KIKristie D. Ibarra
Kristie D. Ibarra
TNThiam-Seng Ng
Thiam-Seng Ng
SSScott A. Smith
Scott A. Smith
JTJoanne L. Tan
Joanne L. Tan
SLShee-Mei Lok
Shee-Mei Lok
An antibody to lock dengue virus out: Mosquito-borne dengue virus (DENV) is a growing public health threat. Nearly 400 million people are infected annually, and no vaccine is currently available. Fibriansah et al. report that a human antibody (2D22) specific for DENV serotype 2, when given therapeutically, can protect mice from a lethal form of this virus. Structural analysis revealed that 2D22 binds across multiple DENV envelope proteins, which probably blocks the ability of these proteins to assemble into the orientation necessary for viral entry. The epitope where 2D22 binds to the virus may therefore represent a potential vaccine target. Science , this issue p. 88

1 August 2004 in Cell
Verified
Journal Article
Closed access
PLPetr Leiman
Petr Leiman
PCPaul R. Chipman
Paul R. Chipman
VKVictor A. Kostyuchenko
Victor A. Kostyuchenko
VMVadim V. Mesyanzhinov
Vadim V. Mesyanzhinov
MRMichael G. Rossmann
Michael G. Rossmann

20 June 2012 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
ETEe Ping Teoh
Ee Ping Teoh
PKPetra Kukkaro
Petra Kukkaro
ETEn Wei Teo
En Wei Teo
ALAngeline P. C. Lim
Angeline P. C. Lim
TTTze Tong Tan
Tze Tong Tan
PMPaul A. MacAry
Paul A. MacAry
The mechanism of action of a serotype-specific natural human antibody against dengue virus has been identified.

20 February 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
GFGuntur Fibriansah
Guntur Fibriansah
JTJoanne L. Tan
Joanne L. Tan
SSScott A. Smith
Scott A. Smith
RARuklanthi de Alwis
Ruklanthi de Alwis
TNThiam-Seng Ng
Thiam-Seng Ng
SLShee-Mei Lok
Shee-Mei Lok
Dengue virus (DENV) infects ~400 million people annually. There is no licensed vaccine or therapeutic drug. Only a small fraction of the total DENV-specific antibodies in a naturally occurring dengue infection consists of highly neutralizing antibodies. Here we show that the DENV-specific human monoclonal antibody 5J7 is exceptionally potent, neutralizing 50% of virus at nanogram-range antibody concentration. The 9 Å resolution cryo-electron microscopy structure of the Fab 5J7–DENV complex shows that a single Fab molecule binds across three envelope proteins and engages three functionally important domains, each from a different envelope protein. These domains are critical for receptor binding and fusion to the endosomal membrane. The ability to bind to multiple domains allows the antibody to fully coat the virus surface with only 60 copies of Fab, that is, half the amount compared with other potent antibodies. Our study reveals a highly efficient and unusual mechanism of molecular recognition by an antibody.